Travis Weaver, DO
Endocrinology, Diabetes & Metabolism · South Bend, INNPI 1063808772
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,766 of the $3,755 with a category attached, or 73.7%. It is spread thinly across 28 manufacturers, the largest accounting for just 20.0%. 2025 is the largest year on record at $2,197, 2.9 times the $767 reported in 2019.
Across 124 payments — averaging $30.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$750
- Insulet Corporation$495
- Tandem Diabetes Care, Inc.$389
- Amgen$290
- Boehringer Ingelheim$235
- Sanofi-aventis U.S. LLC$215
- plus $1K from 22 others
What the payments were for
- Consulting fees$1755%
- Grants$75020%
- Food & beverage$2,76674%
- Education$642%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $750 |
| Insulet Corporation | 15 | $495 |
| Tandem Diabetes Care, Inc. | 23 | $389 |
| Amgen | 8 | $290 |
| Boehringer Ingelheim | 9 | $235 |
| Sanofi-aventis U.S. LLC | 3 | $215 |
| Lilly USA, LLC | 12 | $194 |
| Corcept Therapeutics | 4 | $190 |
| Amneal Pharmaceuticals LLC | 11 | $176 |
| Novo Nordisk | 6 | $125 |
| Abbott | 3 | $73 |
| Sequel Med Tech, LLC | 3 | $73 |
| Radius Health, Inc. | 3 | $64 |
| Bayer | 3 | $63 |
| Dexcom, Inc. | 3 | $58 |
| Medtronic | 3 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| BETA Bionics, Inc. | 2 | $36 |
| Neurocrine Biosciences, Inc. | 1 | $35 |
| Madrigal Pharmaceuticals | 1 | $35 |
| Cequr Corporation | 1 | $28 |
| Ionis Pharmaceuticals, Inc. | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Soleno Therapeutics, Inc. | 1 | $14 |
| Companion Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,755 in reported general payments places this provider in the 65th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 79 | $82,979 |
| MounjaroTirzepatide | 44 | $47,105 |
| OzempicSemaglutide | 46 | $45,230 |
| JardianceEmpagliflozin | 55 | $44,402 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $30,192 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $17,506 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $6,549 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $1,477 |
| Levothyroxine Sodium | 69 | $727 |
| Hydrocortisone | 11 | $673 |
| Insulin Lispro | 11 | $638 |
| Methimazole | 32 | $376 |
| Cabergoline | 14 | $362 |
| Liothyronine Sodium | 12 | $322 |
| Telmisartan | 13 | $258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro | $194 | $130,721134 claims |
| Novo NordiskOzempic | $125 | $45,23046 claims |
| Boehringer IngelheimJardiance | $235 | $44,40255 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $176 | $72769 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in South Bend
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
- Michael EconsIndianapolis$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.